Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ...
Sol-Gel Technologies Ltd.: Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proo ...
ascopubs.org28d
Microsatellite Instability and Clinical Use in Sarcomas: Systematic Review and Illustrative Case Report
Sarcomas, a diverse group of malignancies, exhibit substantial heterogeneity in both biological behavior and microenvironment, influencing their response to immunotherapy. Although pembrolizumab is ...
Medscape8d
Basal Cell Carcinoma and the Carcinogenic Role of Aberrant Hedgehog Signaling
† The majority of mutations were found in different exons of the genes analyzed. Several components of the hedgehog (Hh) pathway are crucial to basal cell carcinoma (BCC) tumorigenesis. Primary ...
Frontiers26d
Curcumin as a novel therapeutic candidate for cancer: can this natural compound revolutionize cancer treatment?
Cancer remains one of the leading causes of death worldwide. Despite advances in medical treatments, current therapeutic strategies, including radiotherapy, chemotherapy, targeted therapy, and ...
Frontiers28d
Biological effects in normal human fibroblasts following chronic and acute irradiation with both low- and high-LET radiation
1 Istituto Superiore di Sanità (ISS), Rome, Italy 2 Istituto Nazionale di Fisica Nucleare (INFN) Sezione Roma 1, Rome, Italy Introduction: Radiobiological studies at low dose rates allow us to improve ...